Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.
Debtor-in-process financing up to $55 million could keep the lights on at Karyopharm for its multiple myeloma and myelofibrosis programs as the biotech waits to see if its union with Ayrmid will go through.